Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

240 questions · 247 findings · 23 reviews

No studies found 35 · 14.2%GRADE not reported 13 · 5.3%Very low 50 · 20.2%Low 71 · 28.7%Moderate 65 · 26.3%High 13 · 5.3%

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Acceptability: total withdrawals · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) probably leads to lower all Withdrawals: All doses of certolizumab pegol vs placebo compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Withdrawals due to adverse events · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher withdrawals due to adverse events All doses of certolizumab pegol… compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Sustained virological response · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…

It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (very low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Relapse · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…

It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes relapse compared with standard peginterferon plus ribavirin treatment (very low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

End of treatment response (ETR) · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…

It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (very low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Sustained virological response · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin

Extended peginterferon plus ribavirin treatment for 72 weeks may leads to higher sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Relapse · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin

Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower relapse rate compared with standard peginterferon plus ribavirin treatment (low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

End of treatment response (ETR) · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin

Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Adherance to treatment · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin or participants with detectable…

Extended peginterferon plus ribavirin treatment for 72 weeks probably leads to lower adherance to treatment compared with standard peginterferon plus ribavirin treatment (moderate certainty).

1 finding from 1 review